Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Core Viewpoint - Aeterna Zentaris Inc. is seeking a court order to extend the deadline for holding its annual shareholder meeting to no later than July 31, 2024, to allow former Ceapro Inc. shareholders to participate in the meeting and vote on key matters related to the upcoming merger [1][2]. Group 1: Court Application and Meeting Details - Aeterna has filed an application with the Ontario Superior Court of Justice to extend the time for calling and holding its annual meeting [1][2]. - The court hearing for the application is scheduled for June 3, 2024, at 11:00 a.m. via videoconference [1]. - The Toronto Stock Exchange has granted Aeterna an extension to hold its annual meeting on or before July 31, 2024 [3]. Group 2: Transaction with Ceapro Inc. - The extension is sought to complete the previously announced transaction with Ceapro Inc. before the annual meeting [2]. - Shareholders will vote on the new name and director nominees for the combined company during the annual meeting [2]. - The transaction is expected to close on or about June 3, 2024, subject to obtaining all required approvals [2]. Group 3: Company Overview - Aeterna is a specialty biopharmaceutical company focused on developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products [4]. - The company's lead product, macimorelin, is the first and only FDA and European Commission approved oral test for diagnosing adult growth hormone deficiency [4]. - Aeterna is also developing therapeutic assets for various conditions, including neuromyelitis optica spectrum disorder, Parkinson's disease, hypoparathyroidism, and amyotrophic lateral sclerosis [5].